Stanford Cancer Institute Clinical Trials Office Blog

News & Updates from the SCI-CTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • SCI Clinical Trials Office
  • Stanford Cancer Institute

Anti-CD47 cancer therapy safe, shows promise in small clinical trial

November 1, 2018 - SCI Communications

Ranjana Advani, MD, recently published findings from the anti-CD47 lymphoma study at Stanford. This phase 1 trial tested Hu5F9-G4 in combination with rituximab in patients with non-Hodgkins Lymphoma. Half of the 22 people enrolled had a positive response to the therapy, and about one-third went into complete remission from their cancer.

Dr. Advani is the PI for the study (sponsor: Forty Seven Inc) and is the lead author for the publication in the New England Journal of Medicine.

Kudos to Dr. Advani and her team in the Lymphoma group for your hard work on this clinical trial!

 
Read more:

  • SF Chronicle article
  • Stanford Medicine press release

Blog Submissions

If you have an announcement for the blog, please complete the Comms Request Form.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • kudos
  • OnCore
  • PRISM
  • PRMS
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube